logo
Plus   Neg
Share
Email

Stock Alert: Genprex Hits New 52-week High

Shares of Genprex Inc. (GNPX) touched a new 52-week high in the morning trade on Friday, at $5.75. The stock has been rising since Tuesday and has traded in a range of $3.15 to $5.75 in the past 52 weeks.

On Tuesday, Genprex had said it entered into an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect about 30.3 million people in the U.S, or 9 percent of the U.S. population. We had alerted the readers about the stock on Feb 11.

Under the agreement, the clinical-stage gene therapy company has licensed the patented diabetes gene therapy technology designed by researchers at the University of Pittsburgh. Genprex plans to pursue potential partnerships for the development of this therapy globally and in the U.S. The company will continue its focus on developing its immunogene therapies for cancer, including Oncoprex immunogene therapy, its lead drug candidate for non-small cell lung cancer, in parallel with development of the new diabetes gene therapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
WeWork's parent company, We Company, said it has filed a lawsuit against Japanese conglomerate SoftBank Group Corp. for failing to consummate a $3 billion tender offer for the company's shares. After WeWork's failed attempt at an initial public offering last year, SoftBank acquired a majority stake in the office sharing company in a bailout, severing most ties with WeWork co-founder Adam Neumann. Walgreens is expanding drive-thru testing for the coronavirus to fifteen new locations in seven states across the U.S. later this week. They include Arizona, Florida, Illinois, Kentucky, Louisiana, Tennessee and Texas. The drive-thru locations are part of Walgreens' collaboration with the administration, federal health agencies, and state and local authorities to expand access to COVID-19 testing. iPhone assembler Foxconn, otherwise known as Hon Hai Precision Industry Co. Ltd., is reportedly set to start manufacturing ventilators in the United States in partnership with medical device firm Medtronic plc., as the U.S. braces for the cornavirus (COVID-19) infection peak. Taiwan-based Foxconn will start manufacturing ventilators at its Wisconsin factory within the next four to six weeks.
RELATED NEWS
Follow RTT
>